Delving into the Latest Updates on Ripertamab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Immunoglobulin g1-kappa, anti-(homo sapiens ms4a1 (membrane-spanning 4-domains subfamily a member 1, cd20)), chimeric monoclonal antibody, Immunoglobulin igg1, anti-(human cd20 antigen) (human-mus musculus monoclonal disulfide sct400 .gamma.1-chain), disulfide with human-mus musculus monoclonal sct400 .kappa.-chain, dimer, Recombinant chimeric anti-CD20 monoclonal antibody

+ [7]

Target

CD20

Mechanism

CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects

+ [1]

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Diffuse Large B-Cell Lymphoma

Inactive Indication

CD20 Positive B-Cell Non-Hodgkin LymphomaCD20 positive Non-Hodgkin LymphomaHodgkin's Lymphoma

Originator Organization

Sinocelltech Group Ltd.

Active Organization

Sinocelltech Group Ltd.

Inactive Organization

Shenzhou Cell Engineering Co. Ltd.

Drug Highest PhaseApproved

First Approval Date

CN (23 Aug 2022),

Diffuse Large B-Cell Lymphoma

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 27145L

Source: *****

Sequence Code 143630H

Source: *****

主要目的：在初治的弥漫性大B细胞淋巴瘤(DLBCL)患者中，以利妥昔单抗联合CHOP (R-CHOP)作为阳性对照，评价SCT400联合CHOP (S-CHOP)作为一线治疗方案的临床有效性。次要目的：评估SCT400联合CHOP (S-CHOP)治疗DLBCL患者的安全性，包括免疫原性。

[Translation]

Primary objective: To evaluate the clinical efficacy of SCT400 combined with CHOP (S-CHOP) as a first-line treatment in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), using rituximab combined with CHOP (R-CHOP) as a positive control. Secondary objective: To evaluate the safety of SCT400 combined with CHOP (S-CHOP) in the treatment of patients with DLBCL, including immunogenicity.

Start Date19 Oct 2016

Sponsor / Collaborator

Shenzhou Cell Engineering Co. Ltd.

100 Clinical Results associated with Ripertamab

Login to view more data

100 Translational Medicine associated with Ripertamab

Login to view more data

100 Patents (Medical) associated with Ripertamab

Login to view more data

190

Literatures (Medical) associated with Ripertamab

01 Oct 2024·Clinics and Research in Hepatology and Gastroenterology

Giant cell hepatitis associated with autoimmune hemolytic anemia: More evidence for B-cell depletion therapy for a rare immune mediated disease of infancy

Article

Author: Sciveres, Marco ; Maggiore, Giuseppe

Giant cell hepatitis associated with autoimmune hemolytic anemia (GCH-AHA) is a rare but severe disease of infancy defined by an acute liver injury, histologically characterized by a widespread giant cell transformation and by an autoimmune hemolysis. GCH-AHA is thought to be immune-mediated being however a distinct entity from juvenile autoimmune hepatitis. In particular, GCH-AHA displays a less favorable response to conventional immunosuppressive treatment compared to classical juvenile autoimmune hepatitis, carrying a higher risk of mortality. In fact, since his first description, conventional therapy with prednisone with azathioprine has been used as first line treatment, however with frequent relapses during tapering, as well as severe side effects related to its prolonged use at high doses in early age. Due to the frequent occurrence of relapse, several immunosuppressive drugs have been tried as second line therapy with doubtful success. In case of severe liver dysfunction and/or severe anemia, transitory remission has been achieved with intravenous immunoglobulins administration, however with temporary response. B-cell depletion treatment, mostly with chimeric anti-CD20 monoclonal antibody (rituximab; RTX) has been used since 2004 with encouraging results mostly in refractory cases as second-line therapy. In this issue, the report of a series of 20 children with GCH-AHA from Shanghai, China, confirms the previous treatment experiences of a greater efficacy in obtaining complete remission of RTX or RTX treatment regimens compared to conventional regimens, with a good safety. To date, published experience with this rare disease suggests that RTX should be considered the cornerstone of treatment for complicated or relapsing cases of GCH-AHA and given the increasing evidence on its efficacy and safety, RTX might be even an acceptable option as first line therapy beside conventional treatment, to drastically reduce the cumulative steroids exposure and its side effects.

01 Jul 2024·Clinical Case Reports

Rituximab‐induced serum sickness in immunobullous disorders: A case series

Article

Author: Gheisari, Mehdi ; Safari Giv, Toktam ; Zaresharifi, Shirin ; Pourgholi, Elnaz

Key Clinical MessageRituximab‐induced serum sickness (RISS) is a rare complication of Rituximab (RTX) in immunobullous disorders. Clinicians should be aware of the occurrence of serum sickness symptoms during RTX administration, and prompt initiation of corticosteroid therapy is crucial in these patients. Additionally, RISS may occur with subsequent RTX doses and patients should be counseled accordingly.AbstractRituximab (RTX) is a chimeric monoclonal anti‐CD20 antibody which has gained approval for the treatment of various autoimmune and lymphoproliferative disorders. While RTX‐induced minor reactions, including immediate infusion‐related reactions, are common, serum sickness is rare. Limited data exist regarding rituximab‐induced serum sickness (RISS) in pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP). We report two cases of RISS following RTX administration in PV and MMP patients. Both patients presented with typical symptoms of serum sickness after RTX infusion, necessitating drug cessation and corticosteroid therapy for resolution. RISS represents a rare complication of RTX therapy. Clinicians should maintain awareness of serum sickness presentations during and post‐RTX administration.

18 Jul 2023·BMC nephrology

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports.

Article

Author: Li, Xianhua ; Yang, Xiangdong ; Xiao, Xiaoyan ; Song, Yiyun ; An, Xin ; Zhao, Yi ; Ding, Lin

Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We herein report two cases of symptomatic hypokalemia after intravenous rituximab administration in our center, to help health professionals consider the possibility of acute hypokalemia after rituximab administration, monitor potassium timely and develop an appropriate treatment plan.

100 Deals associated with Ripertamab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16314

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	CN	Sinocelltech Group Ltd.	23 Aug 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CD20 positive Non-Hodgkin Lymphoma	Phase 2	CN	Shenzhou Cell Engineering Co. Ltd.	11 Jul 2015
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Phase 2	CN	Shenzhou Cell Engineering Co. Ltd.	25 Jun 2012
Hodgkin's Lymphoma	Phase 2	CN	Shenzhou Cell Engineering Co. Ltd.	25 Jun 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02206308 (Pubmed \| Chin J Cancer Res) Manual	Phase 1	CD20 positive Non-Hodgkin Lymphoma CD20 Positive	15	Ripertamab	(uyhkessyeb) = Under premedication, the drug-related infusion reaction was mild. iyhnjzpajf (jmgsrbtztu ) View more	Positive	01 Apr 2016